AARTIPHARM Q1 FY27 Guidance vs Delivery (AARTIPHARM Management Mirror)

Xanthine Segment Guided at 900-1,100 Crores for FY27 as Expansion Concludes

Management reported a strong trajectory for the Xanthine segment. In the Dec'25 Qtr concall, management indicated that the expansion project adding 300 tonnes per month (bringing total capacity to roughly 9,000 to 9,600 tonnes per annum) was on track for mechanical completion by Mar'26, with trials slated for Q1 FY27 (Jun'26 Qtr). They projected 50% to 60% average utilization of this new capacity in its first year, scaling to 85% to 90% by FY28. For Mar'26 Qtr, the segment recorded its highest-ever quarterly revenue of Rs.227 Crores (43% of standalone turnover), having operated at full utilization of its pre-expansion 6,000 MTPA capacity, bringing the full FY26 sales to Rs.792 Crores. In the Jun'26 Qtr concall, management confirmed the mechanical closure of the Unit 99 expansion was completed at quarter-end, taking capacity to 9,500 metric tons, with trial production underway. Management initiated full-year FY27 revenue guidance for Xanthine in a range of 900 crores to 1,100 crores, as they plan to ramp up capacity utilization over upcoming quarters, targeting over 80% utilization by FY28 and a 20% to 25% global market share within two years.